Following the departure of Andy Baum from Pfizer's strategy team, the company has received a U.S. FDA Priority Review for its PADCEV and Keytruda combination aimed at treating muscle-invasive bladder cancer, indicating a strong focus on oncology. This development, expected to drive significant revenue growth, comes as Pfizer reports over 70% efficacy in its Lyme disease vaccine from the VALOR trial and expands its oncology pipeline following the recent acquisition of Seagen. Analysts' ratings remain cautious as Pfizer approaches critical regulatory decisions and prepares to capitalize on its enhanced cancer treatment portfolio.
“Former banker brought on to revitalize Pfizer’s $PFE strategy departs his post”
“$PFE $ALPMY FDA Grants Priority Review to sBLA for PADCEV + Keytruda as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility”
“Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus Keytruda in muscle-invasive bladder cancer. This Priority Review sits within the company’s broader oncology focus, alongside its established vaccine and primary care franchises.”
“Priority Review for PADCEV plus Keytruda in muscle-invasive bladder cancer strengthens the oncology story if approval and real world uptake align with trial outcomes.”
“CICC initiated coverage of Pfizer Inc. (NYSE:PFE) with an Outperform rating on April 16, setting a price target of $33.”
“Pfizer Inc. (NYSE:PFE) announced on March 23 topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405.”
“Pfizer Inc. (NYSE:PFE) further stated that the overall results bolster confidence in the vaccine candidate and that the company is planning submissions to regulatory authorities.”
“Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer Inc. (NYSE:PFE), stated that no vaccine is currently available for Lyme disease, and the efficacy shown in the VALOR study of over 70% is 'highly encouraging', creating confidence in the vaccine’s potential to protect against the disease.”
“Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets, and is also involved in developing immunotherapies that help the immune system to recognise and attack cancer cells.”
“Astellas Pharma Inc. and Pfizer Inc. on Monday said the U.S. Food and Drug Administration has granted Priority Review for a supplemental Biologics License Application for perioperative PADCEV in combination with Keytruda as a treatment for patients with Muscle-Invasive Bladder Cancer (MIBC).”
“The current filing seeks to expand the indication to include patients regardless of cisplatin eligibility.”
“The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026.”
.svg&width=160)
%20-%20USA%20-%20UNOCHA.svg&width=160)